Novel targets to treat airway fibrosis

在慢性阻塞性肺疾病（COPD）和哮喘中，气道纤维化或恐吓引起显著的发病率。这些疾病影响10-15%的人口，每年给卫生系统造成11.5亿美元的损失。目前用于治疗COPD和哮喘的治疗方法并没有减少气道纤维化，因此迫切需要开发专门治疗气道纤维化的治疗方法。布莱恩·奥利弗（Brian Oliver）博士与Pharmaxis合作开发了专门治疗纤维化的新疗法

Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specifically treat fibrosis